Serious renal impairment occurs rarely with use of tenofovir DF.

Abstract

PURPOSE:

The purpose of this study was to evaluate the short-term effects (up to 6 months) of tenofovir disoproxil fumarate (DF) use on renal function in patients being treated for HIV-1 infection.

METHOD:

The charts of 447 HIV-1-infected patients who received at least three months of tenofovir DF treatment were reviewed. Data collected included demographics, concurrent antiretrovirals, other concurrent medications, CD4 counts and HIV-1 viral loads, and serum creatinine values while on tenofovir DF. Data collection was truncated at 6 months.

RESULTS:

Baseline serum creatinine (SCr) was 1.0 mg/dL, with a calculated creatinine clearance (CLCr) of 95.2 mL/min (using the Cockroft-Gault equation). There was no significant change in SCr or CLCr at 12 weeks (1.1 mg/dL and 92.7 mL/min, respectively) or 24 weeks (1.1 mg/dL and 92.9 mL/min, respectively). All three patients with grade 2 increases in SCr had other medical reasons for an increased SCr (one patient each had indinavir-associated nephrolithiasis, lactic acidosis, and pancreatitis). No patients experienced any complications from these increases in SCr.

CONCLUSION:

Increases in SCr and CLCr within the first 6 months of tenofovir DF therapy were rare. Although no clinical nephrotoxicity was observed, continued observation of renal function is warranted in patients predisposed to renal impairment.

• Authors: James D Scott, Peter R Wolfe, Robert K Bolan, Bill Guyer
• Journal: HIV clinical trials (HIV Clin Trials) 2006 Mar-Apr Vol. 7 Issue 2 Pg. 55-8 ISSN: 1528-4336 [Print] England
• PMID: 16798620 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Organophosphonates
• Tenofovir
• Creatinine
• Adenine

Topics

• Adenine (adverse effects, analogs & derivatives, therapeutic use)
• Antiretroviral Therapy, Highly Active
• California
• Creatinine (blood)
• HIV Infections (blood, complications, drug therapy)
• HIV-1
• Humans
• Organophosphonates (adverse effects, therapeutic use)
• Renal Insufficiency (blood, chemically induced)
• Retrospective Studies
• Tenofovir